Thursday, June 23, 2022

12:00 13:00 Lunch Symposium: Entering a New Era in Diabetes Care


Univ.-Prof Dr Martin Clodi and

Univ.-Prof Dr. Alexandra Kautzky-Willer


Assoz. Prof Dr. Julia Mader: Insulin and Digital Health

Univ Prof Dr. Harald Sourij: GLP1-RA and cardiometabolic networks

The introduction of the first connected pens opens up new possibilities in the care of patients with diabetes. Together with the diverse possibilities of blood glucose control using CGM, the TIR concept and the first insulin to be administered only once a week, a new era of insulin therapy is beginning.

At the same time, the care of patients with type 2 diabetes and cardiovascular diseases continues to pose new challenges to medicine. GLP-1 RA are convincing with good data from cardiovascular endpoint studies and for the optimal care of patients with high cardiovascular risk, a good collaboration between the disciplines endocrinology and cardiology is beneficial. The first cardiometabolic high-risk outpatient clinic of the University Hospital Graz is presented as a model of holistic care.

15:45 16:15 Snack Symposium: What does the future hold? Innovative and simple diabetes management with an interoperable CGM

Join Dexcom and experts Univ. Prof. Dr. Thomas Stulnig (Wien), Dr. Ingrid Schütz-Fuhrmann (Mödling) and Dr. Lars Stechemesser (Salzburg) for the latest insights and a vivid discussion about how living with diabetes becomes easier and more successful with a Continuous Glucose Monitoring System (CGM) that can be used intolerably. Learn more about why today a CGM should be ‘state of the art’ in glucose measurement and what the new AACE guidelines mean. Hear the expert explanations about everyday coaching and biofeedback can be successfully included in diabetes management.

18:00 19:00 Evening Symposium: SGLT2i have transformed from glucose lowering drugs to multiorgan protective drugs. Join the discussion about the opportunities SGLT2i provide to patients!

SGLT2i from glucose lowering drug to organ protection

Chair & Introduction: Guntram Schernthaner

SGLT2i: A milestone in CKD treatment Säemann Marcus

Reducing mortality in HFrEF: Mörtl Deddo

Friday, June 24, 2022

08:00 09:00 Breakfast Symposium: The Incretin System – Two natural Hormones and their metabolic Actions
Chair: Prim. Univ.Prof. Dr. Thomas StulnigIncretin Hormones – In Health and Type 2 Diabetes –          Assoz.-Prof. Dr. Florian KieferGLP-1-RA – Reality Check of CVOTs – Prim. Univ.Prof. Dr. Peter Fasching
12:15 13:45 Lunch Symposium: Century of diabetes treatment: Where are we going further?


Prof. Thomas Stulnig (Austria), Chairman

Prof. Erifili Hatziagelaki (Greece)

Prof. Nebojsa Lalic (Serbia)

Prof. Peter Kempler (Hungary) ,Chairman

Prof. Anca Pantea Stoian (Romania)

Dr. Prof. Martin Haluzik (Czechia)

Session 1 – 45 min: From glycemic values to holistic approach in treatment of T2DM

Treatment of T2D has evolved beyond just lowering glucose

Prof. Thomas Stulnig

Multifactorial approach in diabetes management:

New perspectives

Prof. Erifili Hatziagelaki

Guideline update: What to take into the consideration?

Prof. Nebojsa Lalic

Scientific discussions & closing remarks

Session 2 – 45 min: Oral Semaglutide in focus – From data to real life experience

Change of disease trajectory with early advantages of GLP-1 RAs in T2D journey

Prof. Peter Kempler

Onboarding with Rybelsus for reaching long-term positive


Prof. Prof. Anca Pantea Stoian

Early multifactorial therapy: What are expectations?

Dr. Prof. Martin Haluzik

Scientific discussions & closing remarks

15:30 16:00 Snack Symposium: Stellenwert des Insulin glargins in der Diabetestherapie – Potenzial von Biosimilars nützen
Chair: Prof. Thomas Stulnig, ATSpeaker: Prof. Peter Fasching, AT
18:00 19:00 Evening Symposium: From EMPA REG OUTCOME to EMPEROR: driving a paradigm shift in diabetes
Download the announcement here.IntroductionProf. T. Stulnig, AT

From EMPA REG OUTCOME to EMPEROR: driving a paradigm shift in diabetes

Prof. P. Seferović, SRB

Expert panel discussion

Q&A session

Prof. T. Stulnig, AT; Prof. P. Seferović, SRB

Prof. N. Lalić, SRB

The world of diabetes has changed profoundly in September 2015, when the results of EMPA REG OUTCOME© were disclosed, and ever since treatment paradigms shifted from glucocentricity to the holistic view reflected in current guidelines. A surprising outcome of EMPA REG OUTCOME© was the reduction of risk for hospitalization for heart failure, making it a focus of following studies, including dedicated heart failure trials. With the understanding of the early incidence and significant prevalence heart failure has in diabetes patients, what can we learn from the available data, and how can we implement it in our clinical practice?

Date of preparation May 2022

Saturday, June 25, 2022

08:00 09:00 Breakfast Symposium: Basal insulins and time in range – are we ready for change?
Introduction by chairman
Prof. Dr. Péter Kempler, BudapestInvestigating basal insulins in type 1 diabetes – Insights from the InRange study
Prof. Dr. Tadej Battelino, LjubljanaLife demands flexibility – Can modern insulins deliver?
Prof. Dr. Yvonne Winhofer-Stöckl, Vienna

Panel discussion and closing remarks

There is growing evidence for the usefulness of continuous glucose monitoring in the management of patients with type 1 diabetes. In this scientific symposium we aim to present the recent data from the prospective randomized trial comparing second generation basal insulins for the first-time using time-in-range as a primary outcome measure (InRange study) and also discuss the potential impact of the more recent data in the clinical routine. In addition, we will provide insights into topics like dose management in people with type 1 diabetes with active lifestyle performing exercise, switch of insulin therapy etc. Join us for this interesting session and meet the experts!

11:10 11:40 Snack Symposium: Advanced Lipid Therapy – Patient‘s Voice, Doctor’s Choice

Speaker: Dr. Florian Höllerl, AT